4 Experts Available for Timely Analysis on SCOTUS Abortion Pill Case
On Monday, the Supreme Court temporarily extended nationwide access to mifepristone, including access through telehealth and mail, while the justices consider whether to allow new restrictions imposed by the Fifth Circuit to take effect. The case could have major implications not only for abortion access but also for federal drug regulation, telemedicine, and state authority over FDA-approved medications.
For reporters looking for legal, medical, political, or public health insights on this developing story, the following experts are available:
Baker has written five books and dozens of scholarly articles on women’s rights and feminist activism. Her most recent book is Abortion Pills: US History and Politics, published open access with Amherst College Press. She regularly covers developments on abortion pills at Ms. Magazine.
Golden has been on global and national research teams that focused on STI/infertility and abortion clinic capacity. Her current research interests include relationship building during pregnancy via telehealth between provider and patient, pathways to midwifery workforce, innovations in family planning access, and increasing abortion workforce and capacity.
Huberfeld's research focuses on the intersection of health law and constitutional law, often studying law as a structural determinant of health. She frequently publishes on federalism in health care, including health reform, Medicaid, and the post-Dobbs reproductive health landscape. She has more than 100 publications, including two leading health law casebooks. Her work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts, as well as by federal and state agencies.
Upadhyay is a public health social scientist trained in epidemiology and demography. Her expertise is in abortion safety, abortion access in the U.S., medication abortion, and state-level abortion restrictions.